AdvaMed on price transparency
This article was originally published in The Gray Sheet
Executive Summary
Healthcare value measures should incorporate clinical outcomes of entire episodes of care and should not be based solely on cost or "artificially fixed time periods," according to a 1policy position passed by AdvaMed's board Dec. 14. The trade group adds that measures should risk-adjust for patient complexity, place minimal burdens on providers, and ensure continued access to the full array of medical technologies. The position follows an August order by President Bush requiring four government agencies to begin transparency initiatives in January that will make price and quality of care data publicly available (2"The Gray Sheet" Aug. 28, 2006, p. 16)...
You may also be interested in...
Device Firms Would Have To Report Sales Prices To CMS Under Senate Bill
A bill introduced Oct. 23 in the Senate would require device makers seeking Medicare reimbursement to report to CMS the prices they negotiate with hospitals and other buyers for all implantable medical devices
Administration Unveils Transparency Initiatives; Private Sector Follows Suit
The Bush Administration took several steps last week in its agenda for improving public access to price and quality information on healthcare procedures, and some private insurers have followed suit
Belgium Aims To Drive Biologic Competition Through Tendering
New tendering rules in Belgium aim to improve competition between biosimilars and originators, for example by setting contract durations for tendering contracts and limiting the criteria for such contracts.